Are all KRAS mutations created equal?

The Lancet Oncology

Volumn 12, Issue 8, 2011, Pages 717-718

  Stinchcombe, Thomas E ^a   Der, Channing J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; NAVELBINE; PANITUMUMAB;

COLORECTAL CANCER; GENE; GENE MUTATION; HUMAN; KRAS GENE; LETTER; LUNG NON SMALL CELL CANCER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 79960893966     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70200-5     Document Type: Letter

References (9)

1. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011, published online July 21. 10.1016/S1470-2045(11)70189-9.
2. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091-2096.
3. Center for Drug Evaluation and Research. Cetuximab (Erbitux) and panitumumab (Vectibix). Class labeling changes to anti-EGFR monoclonal antibodies, cetuximab (Erbitux) and panitumumab (Vectibix): KRAS mutations US Food and Drug Administration, (accessed July 13, 2011). http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm172905.htm.
4. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010, 304:1812-1820.
5. Tejpar S, Bokemeyer C, Celik I, Schlichting M, Sartorius U, Van Cutsem E Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. Proc Soc Am J Clin Oncol 2011, 29(suppl):3511. (abstr).
6. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. J Clin Oncol 2010, 28:4769-4777.
7. Catalogue of somatic mutations in cancer Wellcome Trust Sanger Institute, (accessed July 12, 2011). http://www.sanger.ac.uk/genetics/CGP/cosmic/.
8. Cox AD, Der CJ Ras history: the saga continues. Small Gtpases 2011, 1:2-27.
9. Vigil D, Cherfils J, Rossman KL, Der CJ Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. Nat Rev Cancer 2010, 10:842-857.